Last reviewed · How we verify

NCT04585412

Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

Completed Phase 4 Last updated 4 August 2021
What this trial tests

Phase 4 trial testing Palonosetron in Chemotherapy-induced Nausea and Vomiting, Prophylaxis in 16 participants. Completed in 31 December 2020.

Timeline
17 August 2020
Primary endpoint
24 October 2020
31 December 2020

Quick facts

Lead sponsorYung Shin Pharm. Ind. Co., Ltd.
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment16
Start date17 August 2020
Primary completion24 October 2020
Estimated completion31 December 2020
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Yung Shin Pharm. Ind. Co., Ltd. — full company profile →

Who can join

Adults 20 to 45, any sex, with Chemotherapy-induced Nausea and Vomiting, Prophylaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of palonosetron after intravenous administration of palonosetron in healthy volunteers under fasting conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Palonosetron

Trials testing the same drug.

Other Yung Shin Pharm. Ind. Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04585412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing